| Octet® BLI Advancing GLP-1 Analog Development |
| Glucagon-like peptide-1 (GLP-1) receptor agonists, once diabetes treatments, have exploded into popular culture as a powerful weight-loss medicine. With oral formulations now reaching the market, GLP-1s may turn out to be the drug class of a decade. |
| Our latest app note outlines structure–function methods and Octet® BLI workflows to measure binding kinetics and affinity for Victoza® (liraglutide), Trulicity® (dulaglutide), and Ozempic® (semaglutide). Therapeutic researchers can learn how amino‑acid and fatty‑acid modifications enhance stability & efficacy, with one analog showing higher affinity than its competitors. |
|
|
|
